⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AZN News
AstraZeneca PLC
Global Drug Discovery Market Projected to Surpass USD 174.92 Billion by 2035 – SNS Insider
globenewswire.com
MRK
AZN
SNY
ROG
NVS
AI4 2026 Unveils World-Class Speaker Lineup Reflecting the Accelerating Impact of AI Across Every Major Industry
accessnewswire.com
CSCO
PYPL
AZN
F
CAT
TCOM
TRU
Top 10 Great Reasons to Visit Velocity Invitational at Sonoma Raceway This Weekend!
globenewswire.com
TSLA
GM
RACE
PAG
HOG
F
VWAGY
RIVN
LCID
NIO
XPEV
WKHS
HYMC
CHPT
EVGO
BLNK
PSNY
PGR
GE
GOOG
META
AMZN
MSFT
NVDA
AMD
INTC
QCOM
MU
AMAT
ASML
LRCX
KLAC
TER
ADI
NXPI
ON
MCHP
AEHR
ENPH
SEDG
PLUG
FCEL
BE
BALL
CPRT
CAR
AZZ
ALGN
BIIB
REGN
GILD
AMGN
BMY
MRK
PFE
JNJ
ABBV
AZN
SNOW
DDOG
CRWD
PANW
FTNT
OKTA
SMCI
CRIS
EDIT
BEAM
NTLA
BNTX
MRNA
COIN
PYPL
MP
PLTR
AI
UPST
SOFI
HOOD
ETSY
MELI
BABA
JD
NFLX
DIS
CMCSA
EA
TTWO
RBLX
AI Supercomputing Platform Market Research 2026-2032: Competition Intensifies as NVIDIA Leads While AMD, Intel and Hyperscalers Expand Custom Silicon Strategies
globenewswire.com
NVDA
AMD
INTC
HPE
DELL
MSFT
AMZN
GOOG
ORCL
SMCI
MU
META
TSM
BRO
CSCO
IBM
ARM
AMAT
LRCX
KLAC
QCOM
CRSP
REGN
GILD
BMY
MRNA
BIIB
EXAS
ILMN
VRTX
AZN
PFE
JNJ
AMGN
LLY
ABBV
BKR
XOM
CVX
NEE
DUK
SO
ED
PCG
SRE
AEP
WEC
ETR
NI
XEL
NRG
CEG
EIX
FE
D
CMS
PNW
ES
$9.5+ Bn ADC Technology Market Industry Trends and Global Forecasts to 2040 - More Than 50% of the Technology Providers Have Signed Multiple Partnerships to Out-license Their Technologies
globenewswire.com
TMDX
GILD
AZN
Form 8-K
sec.gov
MKC-V
MKC
AZN
ZM
Sonar Named a Leader in the 2026 Gartner® Magic Quadrant™ for Technical Debt Management Tools
prnewswire.com
NVDA
NOW
BKNG
GS
AZN
F
Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer
globenewswire.com
AZN
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
globenewswire.com
AZN
ABBV
GILD
BMY
DATROWAY ® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
businesswire.com
AZN